ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Core Viewpoint - ABVC BioPharma, Inc. has entered into a term sheet with OncoX BioPharma, Inc. for a licensing agreement concerning its Oncology/Hematology pipeline, which is expected to significantly enhance the company's market position and financial outlook [1][2]. Group 1: Licensing Agreement Details - The licensing agreement will cover clinical trial, registration, manufacturing, supply, and distribution rights for the Licensed Products [1]. - ABVC is set to receive $50 million in licensing fees and an additional $5 million milestone payment after the first fundraising round, along with 5% royalties on net sales, capped at $50 million [1]. - OncoX will have exclusive global rights to develop and commercialize the Licensed Products and will be responsible for regulatory filings and commercialization efforts [3][4]. Group 2: Product Pipeline and Market Potential - ABVC's product pipeline includes six drugs and one medical device, with ongoing clinical development supported by partnerships with renowned research institutions [6]. - The global cancer therapeutics market is projected to grow from $164 billion in 2022 to approximately $393.61 billion by 2032, reflecting a CAGR of 9.20% from 2023 to 2032 [5].